Alteplase

Overview

Nizatidine is oral H-2-receptor antagonist similar to cimetidine, famotidine, and ranitidine. It currently is indicated for gastroesophageal reflux disease (GERD), short-term and maintenance treatment of duodenal ulcer, and short-term treatment of active benign gastric ulcer. It was originally approved by the FDA in April 1988. It competitively inhibits the binding of histamine to the H-2-receptors on the gastric basolateral membrane of parietal cells, reducing basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin. It may aid in gastromucosal healing, and it may protect the mucosa from the irritant effects caused by aspirin and nonsteroidal antiinflammatory agents..

Categories

• 10 Drugs affecting the blood
  • 10.2 Anticoagulants/Platelet deaggregators

• 12 Cardiovascular drugs
  • 12.5 Anti-thrombotic drugs and myocardial infarction

Page headings

Primary Characterstics

Indications

Pharmacokinetics

Contraindications

Drug Interactions

Side Effects

Dosage

Alteplase's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
10 to 10 mg	10 (10)	As recommended.	IV	This is the dose for pulmonary embolism. Give this initial IV dose over 1-2 minutes. This dose should be followed by 90mg by intravenous infusion over 2 hours, maximum 1.5 mg/Kg in patients less than 65 Kg.
15 to 15 mg	15 (15)	As recommended.	IV	This is the accelerated regimen for myocardial infarction. Initiate within 6 hours of symptom onset. This dose should be followed by 50mg by intravenous infusion over 30 minutes, then 35 mg over 60 minutes (total 100 mg over 90 minutes).
15 to 15 mg	15 (15)	As recommended.	IV	This is the accelerated regimen for myocardial infarction for patients less then 65 Kg weight. This dose should be followed by 0.75mg/Kg by intravenous infusion over 30 minutes, then 0.5mg/Kg over 60 minutes (total 100 mg over 90 minutes).
10 to 10 mg	10 (10)	As recommended.	IV	This is for myocardial infarction within 6-12 hours of symptom onset. This dose should be followed by 50mg by intravenous infusion over 60 minutes, then 4 infusions each of 10mg over 30 minutes (total 100 mg over 3 hours; maximum 1.5 mg/Kg in patients less than 65 Kg).
900 to 900 mcg/Kg	900 (900)	As recommended.	IV	This is the dose for acute stroke initiate within 4.5 hours of symptom onset. Infuse over 60 minutes (Maximum 90 mg); initial 10% dose by intraveous injection, remainder by IV infusion.
Paedriatic Dosage (20kg)
0.75 mg/kg	0.75 (0.75)	As recommended.	Intra Venous	As Required
100 to 500 mcg/kg.hour	300 (300)	As recommended.	IV-Inf	For 3-6 hours; maximum 100 mg total daily dose; use ultrasound assessment to monitor effect before c
Neonatal Dosage (3kg)
100 to 500 mg/kg/hour	300 (300)	As recommended.	IV-Inf	It can be given for 3-6 hours and ultrasound assessment to moniter effect before considering a second cause of treatment.

High Risk Groups

Warning / Precautions

Storage Conditions

Interference in Pathology

Brands / Trade Names of Alteplase

Manufacturers of Alteplase in Pakistan

Back to top